Profil
Meara Murphy is currently working as a Senior Director of Corporate Communications at Pear Therapeutics, Inc. Prior to this, she worked as a Director of Corporate Communications at Lantheus Holdings, Inc. from 2011 to 2019.
During her time at Lantheus Holdings, Inc., she also worked as a Media Relations Contact at Lantheus Medical Imaging, Inc. from 2015 to 2019.
Aktive Positionen von Meara Murphy
Unternehmen | Position | Beginn |
---|---|---|
PEAR THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Meara Murphy
Unternehmen | Position | Ende |
---|---|---|
Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Public Communications Contact | 01.10.2019 |
LANTHEUS HOLDINGS, INC. | Public Communications Contact | 01.10.2019 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
LANTHEUS HOLDINGS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Health Technology |
Pear Therapeutics, Inc.
Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |